ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
,ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
,ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
, ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
f f f f f f f f
1. Afwomanfdiagnosedfwithfobsessive–
compulsivefdisorderfhasfbeenfprescribedforalfparoxetinefhydrochloride.fWhatfisfthefe
xpectedfeffectfforfthisfprescription?
A. Curativefeffectfonfsymptoms
B. Systemicfeffectfonfsymptoms
C. Localfeffectfonfsymptoms
D. Parenteralfeffectfonfsymptoms
ANS:f B
Rationale:fDrugsfthatfproducefsystemicfeffectsfareftakenfintofthefbody,fcirculatedfthroughfthefb
loodstreamftoftheirfsitesfoffactionfinfvariousfbodyftissues,fandfeventuallyfeliminatedffromfthefb
ody.fCurativefagentsfarefgivenftofcurefafdiseasefprocess.fInfthisfcase,fparoxetinefhydrochloridef
willfcontrolfthefsymptomsfbutfnotfcurefthefdisorder.fDrugsfwithflocalfeffects,fsuchfasfsunscreenf
andflocalfanesthetics,factfmainlyfatfthefsitefoffapplication.fParoxetinefhydrochloridefisfnotfadmi
nisteredfparenterally.fParenteralfagentsfarefadministeredfsubcutaneously,fintramuscularly,forfi
ntravenously.
PTS: 1 REF: p.f3,fIntroduction OBJ: 1
NAT:f ClientfNeeds:fPhysiologicalfIntegrity:fPharmacologicalfandfParenteralfTherapiesfT
OP: Chapter:f1:fThefFoundationfoffPharmacology:fQualityfandfSafety
KEY:f IntegratedfProcess:fNursingfProcess
BLM:f CognitivefLevel:fUnderstand NOT:f MultiplefChoice
2. Afclientfhasfbeenfprescribedfanfantibiotic.fThisfmedicationfisfafnaturallyfoccurring
substancefthatfhasfbeenfcheG
mR icA
alDlyEm
SoBdOifOieSd.TWhaOtfM
.C isfanotherfnamefforfthisftypefoffmedica
tion?
A. Syntheticfdrug
B. Semisyntheticfdrug
C. Biotechnologyfdrug
D. Prototypefdrug
ANS:f B
Rationale:fSemisyntheticfdrugsf(e.g.,fmanyfantibiotics)farefnaturallyfoccurringfsubstancesfthatf
havefbeenfchemicallyfmodified.fSyntheticfdrugsfarefmorefstandardizedfinftheirfchemicalfcharact
eristics,fmorefconsistentfinftheirfeffects,fandflessflikelyftofproducefallergicfreactions.fBiotechnol
ogyfdrugsfinvolvefmanipulatingfDNAfandfRNAfandfrecombiningfgenesfintofhybridfmoleculesft
hatfcanfbefinsertedfintoflivingforganisms.fPrototypefdrugsfareftheffirstfdrugfoffafparticularfgroupft
ofbefdeveloped.
PTS: 1 REF: p.f3,fDrugfSources OBJ: 1
NAT:f ClientfNeeds:fPhysiologicalfIntegrity:fPharmacologicalfandfParenteralfTherapiesfT
OP: Chapter:f1:fThefFoundationfoffPharmacology:fQualityfandfSafety
KEY:f IntegratedfProcess:fNursingfProcess
BLM:f CognitivefLevel:fUnderstand NOT:f MultiplefChoice
3. Whichfclassificationfappliesftofmorphine?
A. Centralfnervousfsystemfdepressant
B. Centralfnervousfsystemfstimulant
ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
,ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
,ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
, ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
f f f f f f f f
1. Afwomanfdiagnosedfwithfobsessive–
compulsivefdisorderfhasfbeenfprescribedforalfparoxetinefhydrochloride.fWhatfisfthefe
xpectedfeffectfforfthisfprescription?
A. Curativefeffectfonfsymptoms
B. Systemicfeffectfonfsymptoms
C. Localfeffectfonfsymptoms
D. Parenteralfeffectfonfsymptoms
ANS:f B
Rationale:fDrugsfthatfproducefsystemicfeffectsfareftakenfintofthefbody,fcirculatedfthroughfthefb
loodstreamftoftheirfsitesfoffactionfinfvariousfbodyftissues,fandfeventuallyfeliminatedffromfthefb
ody.fCurativefagentsfarefgivenftofcurefafdiseasefprocess.fInfthisfcase,fparoxetinefhydrochloridef
willfcontrolfthefsymptomsfbutfnotfcurefthefdisorder.fDrugsfwithflocalfeffects,fsuchfasfsunscreenf
andflocalfanesthetics,factfmainlyfatfthefsitefoffapplication.fParoxetinefhydrochloridefisfnotfadmi
nisteredfparenterally.fParenteralfagentsfarefadministeredfsubcutaneously,fintramuscularly,forfi
ntravenously.
PTS: 1 REF: p.f3,fIntroduction OBJ: 1
NAT:f ClientfNeeds:fPhysiologicalfIntegrity:fPharmacologicalfandfParenteralfTherapiesfT
OP: Chapter:f1:fThefFoundationfoffPharmacology:fQualityfandfSafety
KEY:f IntegratedfProcess:fNursingfProcess
BLM:f CognitivefLevel:fUnderstand NOT:f MultiplefChoice
2. Afclientfhasfbeenfprescribedfanfantibiotic.fThisfmedicationfisfafnaturallyfoccurring
substancefthatfhasfbeenfcheG
mR icA
alDlyEm
SoBdOifOieSd.TWhaOtfM
.C isfanotherfnamefforfthisftypefoffmedica
tion?
A. Syntheticfdrug
B. Semisyntheticfdrug
C. Biotechnologyfdrug
D. Prototypefdrug
ANS:f B
Rationale:fSemisyntheticfdrugsf(e.g.,fmanyfantibiotics)farefnaturallyfoccurringfsubstancesfthatf
havefbeenfchemicallyfmodified.fSyntheticfdrugsfarefmorefstandardizedfinftheirfchemicalfcharact
eristics,fmorefconsistentfinftheirfeffects,fandflessflikelyftofproducefallergicfreactions.fBiotechnol
ogyfdrugsfinvolvefmanipulatingfDNAfandfRNAfandfrecombiningfgenesfintofhybridfmoleculesft
hatfcanfbefinsertedfintoflivingforganisms.fPrototypefdrugsfareftheffirstfdrugfoffafparticularfgroupft
ofbefdeveloped.
PTS: 1 REF: p.f3,fDrugfSources OBJ: 1
NAT:f ClientfNeeds:fPhysiologicalfIntegrity:fPharmacologicalfandfParenteralfTherapiesfT
OP: Chapter:f1:fThefFoundationfoffPharmacology:fQualityfandfSafety
KEY:f IntegratedfProcess:fNursingfProcess
BLM:f CognitivefLevel:fUnderstand NOT:f MultiplefChoice
3. Whichfclassificationfappliesftofmorphine?
A. Centralfnervousfsystemfdepressant
B. Centralfnervousfsystemfstimulant
ABRAMS'fCLINICALfDRUGfTHERAPY:fRATIONALESfFORfNURSINGfPRACTICE
